These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29604902)

  • 1. Serum Levels of Soluble FLT3 Ligand in Patients with Active Multiple Myeloma Constitute Marker of Bone Marrow Plasma Cell Proliferative Activity.
    Kokonozaki M; Kanellou P; Pappa CA; Vyzoukaki R; Sarantoulaki S; Stavroulaki E; Kyriakaki S; Alegakis A; Boula A; Alexandrakis MG
    Crit Rev Oncog; 2017; 22(3-4):255-262. PubMed ID: 29604902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
    Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
    Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
    Kokonozaki M; Tsirakis G; Devetzoglou M; Kyriakaki S; Antonakis A; Vyzoukaki R; Pappa CA; Tzardi M; Alexandrakis MG
    Leuk Res; 2015 Dec; 39(12):1467-72. PubMed ID: 26521986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of soluble Fas ligand reflect disease progression in multiple myeloma.
    Alexandrakis MG; Pappa CA; Kolovou A; Kyriakaki S; Vyzoukaki R; Devetzoglou M; Tsirakis G
    Med Oncol; 2014 May; 31(5):953. PubMed ID: 24729186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma.
    Alexandrakis MG; Roussou P; Pappa CA; Messaritakis I; Xekalou A; Goulidaki N; Boula A; Tsirakis G
    Biomed Res Int; 2013; 2013():389579. PubMed ID: 23936794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
    Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
    Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
    Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of interleukin 16 in multiple myeloma.
    Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
    J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma.
    Alexandrakis MG; Passam FH; Kyriakou DS; Dambaki K; Niniraki M; Stathopoulos E
    Am J Clin Oncol; 2004 Feb; 27(1):8-13. PubMed ID: 14758126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
    Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
    Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma.
    Steiner N; Hajek R; Sevcikova S; Borjan B; Jöhrer K; Göbel G; Untergasser G; Gunsilius E
    PLoS One; 2017; 12(7):e0181487. PubMed ID: 28727816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of interleukin-22 in multiple myeloma.
    Tsirakis G; Pappa CA; Kolovou A; Kokonozaki M; Neonakis I; Alexandrakis MG
    Hematology; 2015 Apr; 20(3):143-7. PubMed ID: 25055724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma.
    Jurisić V; Colović M
    Med Oncol; 2002; 19(3):133-9. PubMed ID: 12482123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients.
    Tsirakis G; Pappa CA; Kaparou M; Katsomitrou V; Hatzivasili A; Alegakis T; Xekalou A; Stathopoulos EN; Alexandrakis MG
    Eur J Histochem; 2011; 55(3):e21. PubMed ID: 22073368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
    Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
    Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
    Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
    Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
    PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.